Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd (CAPLIPOINT) last reported results for the quarter ended Jun 2026, with sales of ₹610 crore and net profit of ₹179 crore. The stock last traded at ₹2,602, a market capitalisation of ₹19,774 crore, on a P/E of 29.7. Over the past 52 weeks the stock has ranged between ₹1,500 and ₹2,991. Figures are as of 6 Oct 2026 and are not real time.
Caplin Point Laboratories Ltd share price and key metrics
- Current price
- ₹2,602
- Market cap
- ₹19,774 cr
- Stock P/E
- 29.7
- Book value
- ₹443
- ROE
- 20.9%
- ROCE
- 24.2%
- Dividend yield
- 0.31%
- 52w high / low
- 2991/1500
Metrics as of 6 Oct 2026. Not real time.
Track Caplin Point Laboratories Ltd
Cruxal reads every Caplin Point Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Caplin Point Laboratories Ltd growth and returns
- 10 Years
- 25%
- 5 Years
- 16%
- 3 Years
- 14%
- TTM
- 15%
- 10 Years
- 30%
- 5 Years
- 21%
- 3 Years
- 19%
- TTM
- 18%
- 10 Years
- 25%
- 5 Years
- 24%
- 3 Years
- 34%
- 1 Year
- 29%
- 10 Years
- 25%
- 5 Years
- 23%
- 3 Years
- 22%
- Last Year
- 21%
Caplin Point Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹610 cr, up 19.6% from ₹510 cr a year earlier. Net profit was ₹179 cr, up 18.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 |
| Expenses | 318 | 331 | 334 | 332 | 345 | 353 | 396 | 397 |
| Operating profit | 165 | 162 | 168 | 178 | 189 | 190 | 204 | 213 |
| OPM % | 34% | 33% | 33% | 35% | 35% | 35% | 34% | 35% |
| Other income | 21 | 31 | 26 | 23 | 30 | 34 | 28 | 34 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 17 | 16 | 17 | 16 | 18 | 19 | 19 | 22 |
| Profit before tax | 168 | 177 | 177 | 184 | 201 | 204 | 213 | 225 |
| Tax % | 22% | 21% | 18% | 18% | 20% | 19% | 19% | 20% |
| Net profit | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 |
| EPS (₹) | 17.21 | 18.28 | 18.76 | 20.10 | 20.32 | 21.56 | 22.38 | 23.27 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Caplin Point Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 2,187 | 2,287 |
| Operating profit | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 651 | 765 | 797 |
| OPM % | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% | 34% | 35% | 35% |
| Net profit | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 650 | 678 |
| EPS (₹) | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 84.36 | 87.53 |
TTM is the trailing twelve months to the most recent quarter.
Caplin Point Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 210 | 349 | 582 | 858 | 954 | 1,252 | 1,649 | 2,084 | 2,619 | 3,355 |
| Borrowings | 1 | 1 | 36 | 113 | 235 | 219 | 222 | 219 | 222 | 221 |
| Other liabilities | 133 | 136 | 109 | 139 | 159 | 250 | 305 | 380 | 352 | 446 |
| Total liabilities | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,038 |
| Fixed assets | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 453 | 546 | 580 |
| CWIP | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 | 144 | 234 |
| Investments | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 | 590 | 859 |
| Other assets | 186 | 269 | 436 | 772 | 1,033 | 1,343 | 1,410 | 1,753 | 1,928 | 2,365 |
| Total assets | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,038 |
As reported by the company. Total assets equal total liabilities by construction.
Caplin Point Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 68 | 66 | 83 | 45 | 269 | 337 | 271 | 318 | 432 | 523 |
| Cash from investing | -36 | -69 | -100 | -54 | -30 | -377 | -216 | -319 | -333 | -582 |
| Cash from financing | -7 | -12 | 90 | 80 | -24 | -41 | -28 | -38 | -38 | -46 |
| Net cash flow | 25 | -14 | 73 | 70 | 215 | -81 | 27 | -39 | 61 | -105 |
| Free cash flow | 43 | 18 | 18 | -32 | 195 | 246 | 78 | 173 | 241 | 275 |
| CFO / operating profit | 73% | 53% | 54% | 38% | 102% | 106% | 81% | 77% | 86% | 87% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Caplin Point Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 68% | 63% | 45% | 33% | 28% | 28% | 26% | 26% | 26% | 24% |
| Debtor days | 30 | 85 | 90 | 97 | 96 | 91 | 98 | 117 | 119 | 138 |
| Inventory days | 44 | 44 | 47 | 210 | 139 | 149 | 159 | 183 | 159 | 181 |
| Days payable | 155 | 144 | 76 | 57 | 68 | 102 | 84 | 116 | 103 | 125 |
| Cash conversion cycle | -81 | -16 | 61 | 251 | 166 | 138 | 173 | 184 | 175 | 194 |
| Working capital days | -29 | 47 | 104 | 167 | 145 | 165 | 144 | 166 | 174 | 199 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Caplin Point Laboratories Ltd shareholding pattern
Promoters held 70.57% at Jun 2026, broadly unchanged since Jun 2025. FIIs 5.76% and DIIs 2.49%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.56% | 70.56% | 70.56% | 70.56% | 70.57% | 70.57% | 70.57% | 70.57% |
| FIIs | 3.71% | 4.86% | 5.73% | 6.16% | 6.51% | 6.58% | 6.15% | 5.76% |
| DIIs | 1.83% | 2.11% | 2.00% | 2.22% | 2.10% | 2.05% | 2.14% | 2.49% |
| Public | 23.93% | 22.48% | 21.72% | 21.06% | 20.82% | 20.81% | 21.14% | 21.19% |
| No. of shareholders | 96,123 | 92,702 | 96,387 | 94,169 | 93,753 | 93,705 | 93,896 | 94,385 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Caplin Point Laboratories Ltd corporate filings
- Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter and half year ended September 30, 2026.Company Updatelow impact
- Intimation of Closure of Trading Window for the quarter and half year ended September 30, 2026 commencing from October 01, 2026.Insider Trading / SASTlow impact
- Caplin Point Laboratories Limited Announces Successful Conclusion of 35th Annual General Meeting and Voting ResultsAGM/EGMlow impact
Cruxal's analysis: Caplin Point Laboratories Limited has successfully concluded its 35th Annual General…
Read the full analysis - Caplin Point Laboratories Concludes 35th Annual General Meeting; Re-appoints Managing Director and Appoints New Whole-Time DirectorAGM/EGMlow impact
Cruxal's analysis: Caplin Point Laboratories Limited has successfully concluded its 35th Annual General…
Read the full analysis - Caplin Point Laboratories clarifies on recent stock volume movementCompany Updatelow impact
Cruxal's analysis: Caplin Point Laboratories has issued a clarification regarding the recent surge in…
Read the full analysis - Caplin Point Laboratories Limited announces 35th Annual General Meeting (AGM) for September 25, 2026Company Updatelow impact
Cruxal's analysis: Caplin Point Laboratories Limited has issued a formal notice for its 35th Annual General…
Read the full analysis - Caplin Point Laboratories Limited schedules 35th Annual General Meeting for September 25, 2026Company Updatelow impact
Cruxal's analysis: Caplin Point Laboratories Limited has issued a formal notification regarding its 35th…
Read the full analysis - Caplin Point Laboratories Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Caplin Point Laboratories has submitted its Business Responsibility and Sustainability…
Read the full analysis - Caplin Point Laboratories Announces 35th AGM, Final Dividend of INR 4 per share, and Key Board AppointmentsAGM/EGMmedium impact
Cruxal's analysis: Caplin Point Laboratories Limited has scheduled its 35th Annual General Meeting for…
Read the full analysis - Caplin Point Laboratories Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Caplin Point Laboratories has filed its Annual Report for the financial year 2025-26 as…
Read the full analysis - Caplin Point Laboratories Limited schedules 35th Annual General Meeting for September 25, 2026Company Updatelow impact
Cruxal's analysis: Caplin Point Laboratories Limited has announced the convening of its 35th Annual General…
Read the full analysis - Caplin Point Laboratories subsidiary receives GMP compliance certificate from INVIMACompany Updatemedium impact
Cruxal's analysis: Caplin One Labs Limited, a subsidiary of Caplin Point Laboratories, has received a Good…
Read the full analysis - Caplin Steriles Limited completes unannounced USFDA inspectionCompany Updatemedium impact
Cruxal's analysis: Caplin Point Laboratories announced that its subsidiary, Caplin Steriles Limited, has…
Read the full analysis - Caplin Point Laboratories Limited Files Transcript for Q1 FY 2026-27 Earnings CallCompany Updatelow impact
Cruxal's analysis: Caplin Point Laboratories Limited has formally filed the transcript of its Q1 FY 2026-27…
Read the full analysis - Caplin Point Laboratories Limited releases audio recording of Q1 FY 2026-27 earnings callCompany Updatelow impact
Cruxal's analysis: Caplin Point Laboratories Limited has formally filed the audio recording of its Q1 FY…
Read the full analysis - Caplin Point Laboratories Announces Board Reconstitution: Re-appointment of MD and Elevation of CFO to Whole-Time DirectorCompany Updatelow impact
Cruxal's analysis: Caplin Point Laboratories Limited has announced the re-appointment of Dr. Sridhar Ganesan…
Read the full analysis - Caplin Point Laboratories announces Record Date for 35th AGM and Final Dividend for FY 2025-26Corp. Actionlow impact
Cruxal's analysis: Caplin Point Laboratories Limited has scheduled its 35th Annual General Meeting for…
Read the full analysis - Caplin Point Laboratories Reports Strong Q1 FY27 Results with 20.7% YoY Revenue Growth and Announces Final DividendBoard Meetinghigh impact
Cruxal's analysis: Caplin Point Laboratories Limited delivered a robust performance for the quarter ended…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.